FR2528702A1 - Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase - Google Patents
Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase Download PDFInfo
- Publication number
- FR2528702A1 FR2528702A1 FR8210565A FR8210565A FR2528702A1 FR 2528702 A1 FR2528702 A1 FR 2528702A1 FR 8210565 A FR8210565 A FR 8210565A FR 8210565 A FR8210565 A FR 8210565A FR 2528702 A1 FR2528702 A1 FR 2528702A1
- Authority
- FR
- France
- Prior art keywords
- tiapride
- inhibition
- methoxy
- activity
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 title claims abstract description 11
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 title claims abstract description 11
- 230000005764 inhibitory process Effects 0.000 title claims abstract description 7
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 7
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002547 new drug Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960005344 tiapride Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 22
- 230000001476 alcoholic effect Effects 0.000 abstract description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical class [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 108010006591 Apoenzymes Proteins 0.000 description 2
- 108010025076 Holoenzymes Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 2
- AHXDYBRGGOARRJ-UHFFFAOYSA-N 2-methoxy-5-methylsulfonylbenzamide Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1C(N)=O AHXDYBRGGOARRJ-UHFFFAOYSA-N 0.000 description 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 241001469893 Oxyzygonectes dovii Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008309 brain mechanism Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8210565A FR2528702A1 (fr) | 1982-06-17 | 1982-06-17 | Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase |
| DE19833320187 DE3320187A1 (de) | 1982-06-17 | 1983-06-03 | Verwendung von n-(diethylaminoethyl)-2-methoxy-5-methylsulfonylbenzamid |
| US06/504,419 US4485115A (en) | 1982-06-17 | 1983-06-15 | Method for treating depressive syndrome by administering N-(diethylaminoethyl)-2-methoxy-5-methylsufonyl benzamide |
| IT48506/83A IT1203657B (it) | 1982-06-17 | 1983-06-15 | Impiego in terapia di n-(dietilamminoetil)-2-metossi-5-metilsolfonil-benzammide e medicamento che la contiene |
| DE8383401236T DE3366834D1 (en) | 1982-06-17 | 1983-06-16 | Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase |
| EP83401236A EP0099775B1 (fr) | 1982-06-17 | 1983-06-16 | Application du N-(diéthylaminoéthyl) 2-méthoxy-5-méthylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase |
| AT83401236T ATE22800T1 (de) | 1982-06-17 | 1983-06-16 | Verwendung von n-(diethylaminoethyl)-2-methoxy-5methylsulfonylbenzamiden zur hemmung von tryptophanepyrrolasen. |
| JP58110026A JPS5916823A (ja) | 1982-06-17 | 1983-06-17 | トリプトファン・ピロラーゼ阻害用治療薬 |
| HK561/89A HK56189A (en) | 1982-06-17 | 1989-07-13 | Use of n-(diethylaminoethyl)-2-methoxy-5-methylsulfonyl benzamide for the inhibition of tryptophane pyrrolase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8210565A FR2528702A1 (fr) | 1982-06-17 | 1982-06-17 | Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2528702A1 true FR2528702A1 (fr) | 1983-12-23 |
| FR2528702B3 FR2528702B3 (enExample) | 1985-04-19 |
Family
ID=9275096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8210565A Granted FR2528702A1 (fr) | 1982-06-17 | 1982-06-17 | Application du n-(diethylaminoethyl) 2-methoxy-5-methylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4485115A (enExample) |
| EP (1) | EP0099775B1 (enExample) |
| JP (1) | JPS5916823A (enExample) |
| AT (1) | ATE22800T1 (enExample) |
| DE (2) | DE3320187A1 (enExample) |
| FR (1) | FR2528702A1 (enExample) |
| HK (1) | HK56189A (enExample) |
| IT (1) | IT1203657B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6245371A (ja) * | 1985-08-24 | 1987-02-27 | Toyota Motor Corp | 車両ボデ−外板の塗装方法およびその装置 |
| JPH0767544B2 (ja) * | 1986-12-27 | 1995-07-26 | トヨタ自動車株式会社 | 回転霧化静電塗装装置 |
| EP0520325A1 (de) * | 1991-06-28 | 1992-12-30 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch |
| EP1380292A1 (de) * | 2002-07-03 | 2004-01-14 | Mewicon med. wiss. Beratung GmbH | Tiaprid zur Behandlung von Depressionen |
| US20040224031A1 (en) * | 2003-05-06 | 2004-11-11 | Antonio Zorzano Olarte | Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus |
| WO2023236781A1 (zh) * | 2022-06-10 | 2023-12-14 | 上海日馨医药科技股份有限公司 | 治疗精神类疾病的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791677A (fr) * | 1972-07-19 | 1973-03-16 | Renfag Sa | Procede de preparation de n-(diethylaminoethyl)-2- methoxy-5-methylsulfonyl-benzamide |
| FR2243187B1 (enExample) * | 1973-09-10 | 1978-12-29 | Ile De France | |
| FR2305176A1 (fr) * | 1975-03-28 | 1976-10-22 | Ile De France | Nouveau medicament a base de n-(diethylaminoethyl) 2-methoxy-5-methyl-sulfonyl benzamide |
| JPS5283621A (en) * | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | N-benzyl-n, -benzylethyldiamine derivative |
-
1982
- 1982-06-17 FR FR8210565A patent/FR2528702A1/fr active Granted
-
1983
- 1983-06-03 DE DE19833320187 patent/DE3320187A1/de not_active Withdrawn
- 1983-06-15 IT IT48506/83A patent/IT1203657B/it active
- 1983-06-15 US US06/504,419 patent/US4485115A/en not_active Expired - Lifetime
- 1983-06-16 EP EP83401236A patent/EP0099775B1/fr not_active Expired
- 1983-06-16 AT AT83401236T patent/ATE22800T1/de not_active IP Right Cessation
- 1983-06-16 DE DE8383401236T patent/DE3366834D1/de not_active Expired
- 1983-06-17 JP JP58110026A patent/JPS5916823A/ja active Granted
-
1989
- 1989-07-13 HK HK561/89A patent/HK56189A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0099775B1 (fr) | 1986-10-15 |
| IT1203657B (it) | 1989-02-15 |
| FR2528702B3 (enExample) | 1985-04-19 |
| DE3366834D1 (en) | 1986-11-20 |
| IT8348506A0 (it) | 1983-06-15 |
| JPH0344050B2 (enExample) | 1991-07-04 |
| US4485115A (en) | 1984-11-27 |
| EP0099775A1 (fr) | 1984-02-01 |
| HK56189A (en) | 1989-07-21 |
| ATE22800T1 (de) | 1986-11-15 |
| DE3320187A1 (de) | 1983-12-22 |
| JPS5916823A (ja) | 1984-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1601349A1 (fr) | UTILISATION DE L’ENANTIOMERE (1S, 2R) DU MILNACIPRAN POUR LA PREPARATION D’UN MEDICAMENT | |
| EP0204597A2 (fr) | Utilisation de l'alfuzosine pour le traitement des affections urinaires | |
| EP0278821A1 (fr) | Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis | |
| JPH02500107A (ja) | 即効性／強化された鎮痛作用 | |
| AU2012293702A1 (en) | Treatment of neurodegenerative diseases | |
| JPS62158210A (ja) | Ｌ−ド−パの直腸吸収形態 | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FR2601245A1 (fr) | Nouvelle utilisation de la bromocriptine. | |
| BE1007024A5 (fr) | Compositions a activite agoniste des recepteurs analogues a 5ht1, selective. | |
| EP0099775B1 (fr) | Application du N-(diéthylaminoéthyl) 2-méthoxy-5-méthylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase | |
| EP0471718B1 (fr) | Composition pharmaceutique a base de paracetamol | |
| FR2587213A1 (fr) | Medicament pour le traitement de la dependance aux psychostimulants | |
| FR2705569A1 (fr) | Composition pharmaceutique à base d'une imidazolylcarbazolone destinée à l'administration rectale. | |
| CA2122780C (fr) | Utilisation de la selegiline en medecine veterinaire | |
| FR2579893A1 (enExample) | ||
| EP0029790B1 (fr) | Nouveau médicament à base d'aspirine et d'heptaminol | |
| EP1189617A1 (fr) | Nouvelle association pharmaceutique a activite analgesique contenant du paracetamol et de la buspirone | |
| WO2004037256A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine | |
| WO1996028161A1 (fr) | Utilisation des derives de 2-[4-(azolylbutyl)-piperazinyl-methyl]-benzimidazole pour le traitement de la conjonctivite allergique | |
| LU86290A1 (fr) | Compositions pharmaceutiques a base de 3-aminopropoxyindoles | |
| EP0287469B1 (fr) | Assocation renfermant à titre de principes actifs, un analgésique central et la forskoline | |
| FR2579892A1 (enExample) | ||
| FR2579894A1 (enExample) | ||
| FR2669821A1 (fr) | Utilisation de phenylethanolaminotetralines pour la preparation de medicaments destines au traitement de la depression. | |
| WO2002005817A1 (fr) | Composition pharmaceutique a base de cocaethylene et son utilisation pour le traitement de la dependance aux substances psychoactives |